Maxim Group Downgrades Cyclo Therapeutics to Hold
Portfolio Pulse from Benzinga Newsdesk
Maxim Group has downgraded Cyclo Therapeutics from a Buy to a Hold rating, as per analyst Jason McCarthy.
August 27, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Maxim Group analyst Jason McCarthy has downgraded Cyclo Therapeutics from a Buy to a Hold rating.
The downgrade from Buy to Hold by a reputable analyst can lead to a negative short-term impact on Cyclo Therapeutics' stock price as it may influence investor sentiment and lead to selling pressure.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100